Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Exclusion Criteria

• •1. Ovarian tumors of low malignant potential
• •2. Malignancies other than ovarian cancer within 5 years prior to randomization
• •3. Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period
• •4. Any previous radiotherapy to the abdomen or pelvis
• •5. Known hypersensitivity to used chemotherapeutic agents in this trial and bevacizumab and its excipients, chinese hamster ovary cell products or other recombinant human or humanised antibodies
• •6. Current or recent chronic use of aspirin \> 325 mg/day
• •7. Surgery (including open biopsy) within 4 weeks prior to anticipated first dose of Bevacizumab
• •8. History of VEGF therapy related abdominal fistula or gastrointestinal perforation
• •9. Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease
• •10. Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure
• •11. Previous Cerebro-Vascular Accident , Transient Ischaemic Attack or Sub-Arachnoid Haemorrhage
• •12. Prior history of hypertensive crisis or hypertensive encephalopathy
• •13. Clinically significant disease, including: myocardial infarction or unstable angina within ≤ 6 months of randomization; New York Heart Association (NYHA) \>= grade 2 Congestive Heart Failure; poorly controlled cardiac arrhythmia despite medication; peripheral vascular disease grade \>= 3
• •14. LVEF defined by ECHO/MUGA below the institutional lower limit of normal
• •15. Significant traumatic injury during 4 weeks prior to randomization
• •16. Current brain metastases or spinal cord compression
• •17. History or evidence upon neurological examination of central nervous system disease
• •18. Non-healing wound, active ulcer or bone fracture
• •19. History or evidence of thrombotic or hemorrhagic disorders within 6 months prior to randomization
• •20. Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic coagulation)
• •21. Fertile woman of childbearing potential not willing to use adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) for the duration of the trial and at least 6 months afterwards
• •22. Pregnant or lactating women
• •23. Requirement of therapeutic anticoagulation using marcumar, warfarin or PTT-prolonging heparin